Date: 2013-12-11
Type of information: R&D agreement
Compound:
Company: Medimmune (USA - global biologics arm of AstraZeneca (UK) Johns Hopkins University (USA)
Therapeutic area: Cardiovascular diseases - Metabolic diseases - Respiratory diseases - Inflammatory diseases - Autoimmune diseases - Cancer - Oncology - Infectious diseases - CNS diseases.
Type agreement: R&D
Action mechanism:
Disease: cardiovascular diseases, metabolic diseases, oncology, respiratory diseases inflammation and autoimmunity; infectious disease and neuroscience
Details: * On December 11, 2013, MedImmune, AstraZeneca’s global biologics research and development arm, and the Johns Hopkins University have announced they have entered into a five-year, $6.5 million research collaboration. MedImmune and Johns Hopkins will each contribute funding, personnel and materials to address important scientific questions and exchange knowledge through joint research efforts, training programs and access to specialized knowledge, facilities and equipment.
The joint research projects will focus on MedImmune’s therapeutic areas of interest, including cardiovascular and metabolic disease; oncology; respiratory, inflammation and autoimmunity; infectious disease and neuroscience.
This new collaboration model extends to both MedImmune’s biologics and AstraZeneca’s small molecule portfolios. Some of the key projects include:
- Oncology: exploring the role of immune system cells in tumor growth and harnessing findings to identify new cancer drug targets.
- Respiratory, Inflammation and Autoimmunity: researching the damaging mechanisms underlying rheumatoid arthritis (RA) and validating potential therapeutic targets that may play key roles in the development or progression of RA.
- Infectious disease: assessing monoclonal antibody combinations to aid in clinical candidate selections to more effectively prevent recurrent infections in high risk patients such as those with diabetes. This collaboration builds on MedImmune’s ongoing work to prevent serious and costly drug-resistant infections.
- Antibody Discovery & Protein Engineering: working with the university to find innovative ways to manufacture complex next generation biologic drugs.
Financial terms:
Latest news:
